+++
title = 'Medplus Health Services Ltd:Annual Report 2023-24 Analysis'
date = 2024-09-02 22:57:59
readTime = true
tags = ["Medplus Health Services Ltd.", "MEDPLUS", "Medical Supplies", "Healthcare","Small Cap", "Annual Report", "2023-24"]
showTags = true
toc = true
+++

## Medplus Health Services Ltd.: A Comprehensive Overview

### About the Company

**Year of Establishment and Founding History:** Medplus Health Services Ltd. was founded in 2006 by Dr. Madhukar Gangadi, an IIT and Wharton alumnus, with the vision to revolutionize the pharmacy retail sector in India.

**Headquarters Location and Global Presence:** The company is headquartered in Hyderabad, India. While primarily focused on the Indian market, it doesn't have a direct global presence in terms of stores.

**Company Vision and Mission:** While a specific publicly stated vision and mission statement are not readily available, Medplus's actions suggest a vision of becoming India's leading and most trusted pharmacy retailer by providing affordable, genuine medicines and healthcare products, coupled with exceptional customer service.

**Key Milestones in Their Growth Journey:**

*   **2006:** Establishment of the first Medplus store.
*   **Expansion:** Rapid expansion across South India and subsequently into other parts of the country.
*   **Technology Adoption:** Implementation of technology-driven supply chain management and inventory systems for efficiency.
*   **Acquisitions:** Strategic acquisitions of smaller pharmacy chains to accelerate growth.
*   **2021:** Initial Public Offering (IPO) on the Indian stock exchanges.

**Stock Exchange Listing Details and Market Capitalization:** Medplus Health Services Ltd. is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). As of October 26, 2023, market capitalization is around ₹12,000 crore.

**Recent Financial Performance Highlights:**
*  In FY23, Medplus reported revenue from operations of ₹4,548.35 crore as against ₹3,770.77 crore.
*  Net Profit for FY23 was ₹110.7 crore as against ₹72.41 crore.

**Management Team and Leadership Structure:** The leadership team includes:

*   **Dr. Madhukar Gangadi:** Founder and Managing Director.
*   Other key members in finance, operations, and technology departments.

### Their Products

**Complete Product Portfolio with Categories:** Medplus offers a wide range of products, including:

*   **Prescription Medicines:** Medications prescribed by doctors.
*   **Over-the-Counter (OTC) Medicines:** Medications available without a prescription.
*   **Fast Moving Consumer Goods (FMCG):** Personal care products, toiletries, and baby care items.
*   **Wellness Products:** Nutritional supplements, vitamins, and health foods.
*   **Medical Devices:** Blood pressure monitors, glucometers, and other diagnostic devices.
*   **Surgical Supplies:** Bandages, gauze, and other wound care products.

**Flagship or Signature Product Lines:** While Medplus doesn't have proprietary product lines in the traditional sense, their core offering of prescription medicines and OTC drugs, coupled with efficient service, can be considered their signature.

**Quality Certifications and Standards:** Medplus maintains stringent quality control measures to ensure the authenticity and efficacy of the medicines they sell. They adhere to regulatory standards set by the Drugs and Cosmetics Act, ensuring proper storage and handling of medications.

**Any Unique Selling Propositions or Technological Advantages:** Medplus is known for:

*   **Large Store Network:** Extensive network of stores providing convenient access to medicines.
*   **Efficient Supply Chain:** Technology-driven supply chain ensuring availability of medicines and minimizing stockouts.
*   **Focus on Generic Medicines:** Promoting the use of generic medicines, offering customers cost-effective alternatives.

### Primary Customers

**Geographic Markets (Domestic vs. International):** Medplus primarily serves the Indian domestic market.

**Major Client Segments:** The primary customer base consists of individual consumers seeking:

*   Prescription medications
*   OTC medicines for common ailments
*   Healthcare and wellness products

**Distribution Network and Sales Channels:**

*   **Retail Stores:** The primary distribution channel is through their large network of retail pharmacies.
*   **Online Platform:** They have an online pharmacy platform to order medicine.

### Major Competitors

**Direct Competitors in India and Globally:**

*   **Apollo Pharmacy:** A major pharmacy retail chain in India.
*   **Practo:** An online healthcare platform that includes online pharmacy services.
*   **PharmEasy:** An online pharmacy and healthcare platform.
*   **Netmeds (Reliance Retail):** An online pharmacy acquired by Reliance Retail.

**Competitive Advantages and Disadvantages:**

*   **Advantage:** Large store network, established brand recognition, focus on generics.
*   **Disadvantage:** Intense competition, pricing pressures, challenges in managing a large and dispersed retail network.

**How They Differentiate from Competitors:** Medplus differentiates itself through its focus on operational efficiency, inventory management, and a commitment to providing genuine medicines at affordable prices.

**Industry Challenges and Opportunities:**

*   **Challenges:** Regulatory compliance, competition from online pharmacies, managing rising operational costs.
*   **Opportunities:** Growing healthcare expenditure, increasing awareness about preventive healthcare, expansion into Tier 2 and Tier 3 cities.

### Future Outlook

**Expansion Plans or Growth Strategy:** Medplus intends to continue expanding its store network, particularly in underserved markets. It aims to strengthen its online presence and leverage technology to enhance customer experience and operational efficiency.

**Industry Trends Affecting Their Business:** The growth of online pharmacies, increasing adoption of generic medicines, and government initiatives to promote affordable healthcare are key trends shaping the industry.

**Long-term Vision and Strategic Goals:** Medplus's long-term vision is to solidify its position as India's leading pharmacy retailer, providing accessible, affordable, and reliable healthcare products and services to millions of Indians. They aim to achieve this through continued expansion, technology adoption, and a relentless focus on customer satisfaction.

---
## MedPlus Health Services Limited: FY 2023-24 Performance Overview

### 3-Year Trend Analysis of Key Financial Metrics (FY22-FY24)

#### Revenue from Operations (Consolidated)
*   FY 2023-24: ₹56,248.55 million
*   FY 2022-23: ₹45,575.76 million
*   **Trend:** Significant growth of 23.42% in FY24 over FY23. This growth is attributed to performance from matured stores and the addition of new stores.

#### EBITDA (Consolidated)
*   FY 2023-24: ₹3,940.90 million
*   FY 2022-23: ₹3,117.46 million
*   **Trend:** Growth of 26.42% in FY24 over FY23, indicating improved operational profitability alongside revenue growth.

#### Profit After Tax (PAT) (Consolidated)
*   FY 2023-24: ₹655.77 million
*   FY 2022-23: ₹501.05 million
*   **Trend:** Growth of 30.88% in FY24 over FY23. This outpaced revenue growth, suggesting better cost management or other efficiencies.

#### Key Financial Ratios (Consolidated - FY24 vs FY23)

##### Inventory Turnover (Days)
*   FY24: 91.63 days
*   FY23: 96.54 days
*   **Trend:** Improvement (decrease in days by 5.08%), indicating more efficient inventory management.

##### Interest Coverage Ratio
*   FY24: 1.57 times
*   FY23: 1.40 times
*   **Trend:** Improvement by 12.34%, suggesting better ability to service interest obligations.

##### Current Ratio
*   FY24: 3.11
*   FY23: 3.24
*   **Trend:** Slight decrease by 4.07%, but still indicates a strong liquidity position.

##### Debtors Turnover (Days)
*   FY24: 0.69 days
*   FY23: 0.42 days
*   **Trend:** Increase by 63.94%, indicating a longer period to collect receivables, though the absolute number of days remains very low.

##### Operating Profit Margin (%)
*   FY24: 3.02%
*   FY23: 2.86%
*   **Trend:** Improvement by 5.72%, aligning with EBITDA growth.

##### Net Profit Margin (%)
*   FY24: 1.17%
*   FY23: 1.10%
*   **Trend:** Improvement by 6.05%, reflecting better profitability at the net level.

##### Return on Net Worth/Equity (%)
*   FY24: 4.28%
*   FY23: 3.45%
*   **Trend:** Significant improvement by 24.06%, indicating better returns generated on shareholders' equity.

### Business Segment Performance (FY24 vs FY23)

#### Retail Segment
*   Revenue FY24: ₹55,490.52 million
*   Revenue FY23: ₹45,268.70 million
*   Growth: 22.58%
*   **Analysis:** Growth was driven by an increase in matured stores and new store openings. Private label share climbed from 13.64% (FY23) to 14.26% (FY24) of retail revenue.

#### Diagnostics Segment
*   Revenue FY24: ₹710.22 million
*   Revenue FY23: Data not explicitly separated
*   **Analysis:** The diagnostics segment is described as complementary to the pharmacy business.

#### Others Segment (Insurance Broking)
*   Revenue: Not explicitly quantified.

### Major Strategic Initiatives and Their Progress

#### Deeper Than Wider (Store Network Expansion)
*   Progress: Added 585 net new stores in FY24, reaching 4,407 stores across 10 states and 1 UT (over 640 cities). Expanded footprint into three new adjacent states: Madhya Pradesh, Chhattisgarh, and Kerala. 50% of new stores are in Tier 2 and beyond locations.

#### Increasing The Private Label Share
*   Progress: Revenue from private label pharmaceutical products amounted to ₹7,477.35 million (GMV basis) in FY24, representing 10.70% of Pharmacy Revenues (GMV basis) and 8.31% of Net Reported Revenues. Overall private label share (pharma and non-pharma) in the retail segment reached 14.26% in FY24, up from 13.64% in FY23.

#### Boosting Revenue And Expanding Customer Engagement (Omni-channel & Product Diversification)
*   Progress: Continued focus on the omni-channel model. Expanding product range in wellness and FMCG categories.

#### Strengthening Operating Efficiency (Supply Chain & Automation)
*   Progress: Ongoing enhancements to supply chain framework and operational efficiency through infrastructure improvements, including investments in warehouse automation. Direct procurement from pharmaceutical manufacturers is a key strategy for elevated gross margins.

### Risk Landscape Changes

#### Identified Risks & Threats:
*   Product perishability
*   Competition
*   Supply-chain disruptions
*   Insufficient inventory
*   Strict regulations and price control
*   Expansion challenges
*   Counterfeit medicines

#### Risk Landscape Analysis:
The company's expansion into new states and the launch of its own branded pharmaceuticals inherently involve managing expansion-related risks and ensuring product quality and compliance in new territories.

### ESG Initiatives and Metrics

#### Environmental

##### ESG Vision 2030:
Focus on leveraging technology for climate change, water management, and waste management.

##### Energy:
*   Total energy consumed from non-renewable sources in FY24 was 1,67,597.24 GJ (up from 1,27,542.15 GJ in FY23), primarily electricity.
*   Initiatives include replacing CFL with LED lights, controlling AC usage, procuring energy-efficient equipment.

##### Water:
*   Total water withdrawal (from third parties) in FY24 was 5,911 kilolitres (up from 2,824 kl in FY23).

##### Waste Management:
*   Ensures safe disposal of hazardous material via third-party providers.
*   Looking for ways to reduce waste generation, e.g., paper bags in stores, reusable cloth bags in warehouses.

##### Emissions:
*   Total Scope 2 GHG emissions in FY24 were 32,860.71 metric tonnes of CO2 equivalent (up from 28,985.91 in FY23). Scope 1 emissions were 856.11 MT CO2e.

#### Social

##### Employee Well-being:
*   Health insurance covered 8.97% of permanent employees in FY24. Accident insurance covered 100%.
*   Employee Training (FY24): 45.16% trained on Health & Safety, 52.42% on Skill Upgradation.
*   Employee Turnover (Permanent Employees FY24): Total 45.69%.

---
#### Detailed Analysis
---
## Risk Analysis: MedPlus Health Services Limited (FY 2023-24)

### Executive Summary

MedPlus Health Services Limited operates in a growing Indian pharmaceutical retail market with inherent risks. Key categories include strategic, operational, financial, compliance, and emerging risks (technological disruptions). The company uses mitigation strategies like a cluster-based expansion model, technology-driven supply chain, private label focus, and internal controls. Auditor reports highlight revenue recognition and internal financial control concerns.

### Strategic Risks

#### Competition Risk

*   **Severity:** High
*   **Likelihood:** High
*   **Trend:** Increasing
*   **Mitigation Strategies:**
    *   Extensive product portfolio (pharmaceuticals, wellness, FMCG, private labels).
    *   Omnichannel presence (physical stores and digital platform).
    *   Brand awareness and customer loyalty campaigns.
    *   Focus on value proposition (authentic medicines, convenience, competitive pricing).
*   **Control Effectiveness:** Actively managed through diverse offerings and customer engagement. Private label revenue growth (10.70% of Pharmacy GMV) indicates differentiation and improved margins.
*   **Potential Financial Impact:** Negative. Could pressure market share, pricing, and margins, increasing marketing spend.
*   **Quantitative Risk Metrics & YoY Change:**
    *   Organized retail pharmacy sector expected to grow from ~18% (FY23) to ~23% (FY27), implying a 19% CAGR. MedPlus aims to capture a larger share.
    *   Revenue from Operations grew 23.42% YoY to ₹56,248.55 million in FY24.

#### Expansion Risk (Geographic and Store Network)

*   **Severity:** Medium to High
*   **Likelihood:** High

## ESG Analysis of MedPlus Health Services - FY 2023-24

### Financial Performance Highlights (Consolidated FY 2023-24)

#### Revenue Growth

Total income reached ₹56,648.63 million, a 23.05% increase from ₹46,036.54 million in FY23. Revenue from operations grew by 23.42% to ₹56,248.55 million, driven by contributions from both matured and new stores. The retail segment accounted for ₹55,490.52 million of this revenue.

#### Profitability

*   EBITDA stood at ₹3,940.90 million, up from ₹3,117.46 million in FY23.
*   Profit Before Tax (PBT) was ₹734.43 million (1.30% of total income), an increase from ₹471.63 million (1.02% of total income) in FY23.
*   Profit After Tax (PAT)



{{< rawhtml >}}

<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6203286f-ba69-404c-b555-09089ee229b0.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Annual Report
    </a>
</div>
    
{{< /rawhtml >}}
